“…The baseline or comparison condition varied across studies, including normal performance by healthy animals, poorly-performing animals, or following degradation of performance by task parameter manipulation or brain lesion, pharmacological treatment or sleep deprivation, Drugs producing performance enhancement, though often under specific conditions, have included the following: D1 dopamine receptor agonists (Granon et al 2000; Chudasama and Robbins 2004, but see also Passetii et al 2003), donepezil (Balducci et al 2003; Lindner et al, 2006; Romberg et al 2011), M2 muscarinic, agonist (Terry et al 2010), alpha-7 and alpha-4, beta4 subunit selective nicotinic receptor agonists (Grottick et al 2003; Mohler et a 2010; Semenova et al 2007), ciproxifan (Ligneau et al 1998), sertindole (Carli et al 2011b), aripiprazole (Carli et al 2010b), clozapine (Amitai and Markou 2007), methylphenidate (Paine et al 2010), adrenergic agents (Jakala et al 1992; Puumala et al 1997) reboxetine (Liu et al 2009) and atomoxetine (Robinson 2012). The 5CSRTT has also been used to study performance in genetically modified mice including a genetic model of attention deficit disorder (Davies et al, 2009) or other impulse-control dysfunction (Isles et al, 2004; Lambourne et al, 2007; Oliver et al, 2009; Yan et al, 2011); a triple-transgenic 3×Tg-AD mouse model of Alzheimer’s Disease (Romberg et al, 2011) and alpha 7 nAChR mutant mice (Hoyle et al, 2006; Young et al, 2004).…”